Cargando…

Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data

INTRODUCTION: The objective of this study was to estimate the lifetime risk of hospitalization associated with all major human papillomavirus (HPV)-related diseases in Italy. Moreover, a preliminary vaccination effect was also performed. METHODS: A retrospective, nonrandomized, observational study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcellusi, A., Mennini, F. S., Sciattella, P., Favato, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558199/
https://www.ncbi.nlm.nih.gov/pubmed/34117988
http://dx.doi.org/10.1007/s10198-021-01317-w
_version_ 1784592503077339136
author Marcellusi, A.
Mennini, F. S.
Sciattella, P.
Favato, G.
author_facet Marcellusi, A.
Mennini, F. S.
Sciattella, P.
Favato, G.
author_sort Marcellusi, A.
collection PubMed
description INTRODUCTION: The objective of this study was to estimate the lifetime risk of hospitalization associated with all major human papillomavirus (HPV)-related diseases in Italy. Moreover, a preliminary vaccination effect was also performed. METHODS: A retrospective, nonrandomized, observational study was developed based on patients hospitalized between 2006 and 2018 in Italy. All hospitalizations were identified through administrative archives, according to the International Classification of Diseases (ICD-9 CM). Information related to the hospital discharges of all accredited public and private hospitals, both for ordinary and day care regimes, was taken into account. We included hospitalizations related to resident patients presenting one of the ICD-9-CM codes as primary or secondary diagnosis: genital warts (GW); ‘cervical intraepithelial neoplasia (CIN)’ (067.32–067.33); ‘condyloma acuminatum’ (078.11); ‘anal cancers’ (AC) (154.2–154.8); oropharyngeal cancers (OC): ‘oropharyngeal cancer’(146.0–146.9) and ‘head, face and neck cancers’ (171.0); genital cancers (GC): ‘penis cancer’ (187.1–187.9) and ‘cervical cancer’ (180.0–180.9). Data were stratified by birth year and divided into two groups: (a) cohort born before 1996 (not vaccinable) and (b) cohort born after 1997 (vaccinable—first cohort that could be vaccinated at the beginning of immunization schedule in girls since 2008 in Italy). Disease-specific hospitalization risks for both groups were estimated by sex, year and age. RESULTS: Epidemiological data demonstrate that the peak hospitalization risk occurred at 24–26 years of age for GW (both male and female); 33–41 and 47–54 years for AC males and females, respectively; 53–59 and 52–58 years for OC males and females, respectively; and 54–60 and 39–46 years for GC males and females, respectively. Focusing on GW and GC, vaccinable females demonstrate a significant reduction in hospitalization risks (− 54% on average) compared to nonvaccinable females until 21 years of age (maximum follow-up available for girls born after 1997). Comparing the same birth cohort of males, no differences in hospitalization risk were found. CONCLUSIONS: These results support the importance of primary prevention strategies in Italy and suggest that increased VCRs and time of observation (genital cancers for which vaccination is highly effective, have a latency of some decades) will provide useful information for decision-makers.
format Online
Article
Text
id pubmed-8558199
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85581992021-11-15 Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data Marcellusi, A. Mennini, F. S. Sciattella, P. Favato, G. Eur J Health Econ Original Paper INTRODUCTION: The objective of this study was to estimate the lifetime risk of hospitalization associated with all major human papillomavirus (HPV)-related diseases in Italy. Moreover, a preliminary vaccination effect was also performed. METHODS: A retrospective, nonrandomized, observational study was developed based on patients hospitalized between 2006 and 2018 in Italy. All hospitalizations were identified through administrative archives, according to the International Classification of Diseases (ICD-9 CM). Information related to the hospital discharges of all accredited public and private hospitals, both for ordinary and day care regimes, was taken into account. We included hospitalizations related to resident patients presenting one of the ICD-9-CM codes as primary or secondary diagnosis: genital warts (GW); ‘cervical intraepithelial neoplasia (CIN)’ (067.32–067.33); ‘condyloma acuminatum’ (078.11); ‘anal cancers’ (AC) (154.2–154.8); oropharyngeal cancers (OC): ‘oropharyngeal cancer’(146.0–146.9) and ‘head, face and neck cancers’ (171.0); genital cancers (GC): ‘penis cancer’ (187.1–187.9) and ‘cervical cancer’ (180.0–180.9). Data were stratified by birth year and divided into two groups: (a) cohort born before 1996 (not vaccinable) and (b) cohort born after 1997 (vaccinable—first cohort that could be vaccinated at the beginning of immunization schedule in girls since 2008 in Italy). Disease-specific hospitalization risks for both groups were estimated by sex, year and age. RESULTS: Epidemiological data demonstrate that the peak hospitalization risk occurred at 24–26 years of age for GW (both male and female); 33–41 and 47–54 years for AC males and females, respectively; 53–59 and 52–58 years for OC males and females, respectively; and 54–60 and 39–46 years for GC males and females, respectively. Focusing on GW and GC, vaccinable females demonstrate a significant reduction in hospitalization risks (− 54% on average) compared to nonvaccinable females until 21 years of age (maximum follow-up available for girls born after 1997). Comparing the same birth cohort of males, no differences in hospitalization risk were found. CONCLUSIONS: These results support the importance of primary prevention strategies in Italy and suggest that increased VCRs and time of observation (genital cancers for which vaccination is highly effective, have a latency of some decades) will provide useful information for decision-makers. Springer Berlin Heidelberg 2021-06-12 2021 /pmc/articles/PMC8558199/ /pubmed/34117988 http://dx.doi.org/10.1007/s10198-021-01317-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Marcellusi, A.
Mennini, F. S.
Sciattella, P.
Favato, G.
Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data
title Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data
title_full Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data
title_fullStr Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data
title_full_unstemmed Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data
title_short Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data
title_sort human papillomavirus in italy: retrospective cohort analysis and preliminary vaccination effect from real-world data
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558199/
https://www.ncbi.nlm.nih.gov/pubmed/34117988
http://dx.doi.org/10.1007/s10198-021-01317-w
work_keys_str_mv AT marcellusia humanpapillomavirusinitalyretrospectivecohortanalysisandpreliminaryvaccinationeffectfromrealworlddata
AT menninifs humanpapillomavirusinitalyretrospectivecohortanalysisandpreliminaryvaccinationeffectfromrealworlddata
AT sciattellap humanpapillomavirusinitalyretrospectivecohortanalysisandpreliminaryvaccinationeffectfromrealworlddata
AT favatog humanpapillomavirusinitalyretrospectivecohortanalysisandpreliminaryvaccinationeffectfromrealworlddata